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Women diagnosed with breast or gynecological cancers seeking radiotherapy have not acted like 
typical health care consumers—they value considerably their initial oncologist’s treatment recom-
mendations and put forward a general reluctance to deviate from these agreed initial approaches to 
care under early phase clinical trials evaluating new radiation-agent combinations (1) or hypofrac-
tionated radiotherapy (2, 3). Many female radiotherapy consumers now enter radiation oncology 
clinics as women who are “cancer survivors” knowledgeable of, and treated by, gainful biologic 
plus cytotoxic chemotherapeutic agents, and therefore, anticipate state-of-the-art radiotherapy. 
Fortunately, these female consumers have brand-new radiotherapy options, marketed in part by 
(a) better preclinical radiobiology, which more and more scrutinizes gains from radiation-agent 
combinations, (b) better clinical evidence from early phase clinical trials, extolling leading-edge 
radiation-agent approaches to cancer care, (c) better health care plans, alerting consumers to best 
clinical practices for radiotherapy length of care and shared insurer-insured financial responsibility, 
and (d) better home-town service, where local radiation oncologists provide first-rate radiotherapy 
cancer care.
But, some consumer myths need challenge, including that ovarian, uterine, and uterine cervix 
cancers are increasingly rare, are managed effectively without appreciation of molecular classifica-
tion and are treated best by existing cancer stage-directed therapies.
Ovarian, uterine, and uterine cervix cancers in 2016 add up to be the third most common group 
of cancers in American women (4) but collectively are understudied and are underfunded in overall 
cancer research. For the year 2015, the United States National Institutes of Health (NIH) spent 
$269 million combined for ovarian, uterine, and uterine cervix cancer research, a sum only 40% of 
the $674 million spent for breast cancer research alone (5). There is an increasing unmet scientific 
gap in basic radiobiological cancer research to prime early or late phase clinical trials testing novel 
radiation-agent combinations for the treatment of gynecological cancers. It is imperative that such 
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trials be guided by clinically relevant preclinical experiments that 
inform radiation-agent dose, schedule, exposure, and therapeutic 
effect for purposeful design of next-step clinical trials (6). Only 
then with such data in-hand could radiation-agent combinations, 
showing proof-of-target biomarker modification at clinically 
relevant radiation-agent dose and corresponding antitumor 
response, be prioritized for cancer care consumers seeking mod-
ern radiotherapy.
With fierce oncology market competition and limited 
resources, clinical trialist thought leaders must invest wisely in 
appealing radiotherapy cancer research, focusing on molecularly 
driven, safe, and practical radiation-agent combinations. Most of 
that gainful investment has been measured by early phase clinical 
trials that follow a 3 + 3 patient cohort design (7), recognizing 
trial priorities for participant wellbeing, principled conduct, and 
minimized interruption (8). Anecdotal evidence indicates that 
3 +  3 designed radiation-agent trials might be most attractive 
if radiation course duration was condensed (e.g., 25-day pelvic 
radiation course shortened to 3  days) or if intensified radio-
therapy was co-administered with less toxic administered doses 
of a molecularly targeted radiation/chemotherapy-sensitizing 
drug (e.g., gemcitabine) or conventional anticancer drug (e.g., 
carboplatin), as was done in the 12-patient referent 3 + 3 designed 
trial above (1). But sometimes, cancer care providers need to 
understand which trial service matters most (e.g., shortened 
radiotherapy course) to consumers in a particular disease setting 
and study closely that feature that aligns best with trial agreeable-
ness. In the referent 3 + 3 designed trial above, there might have 
been a missed chance to use an accelerated titration designed trial 
(9)—where only one patient would have been accrued per cohort 
until one patient manifested a predefined dose-limiting toxic 
effect or two sequential patients experienced grade 2 toxic effects. 
When either of these two conditions are met, patient expansion 
occurs in that cohort for a traditional 3 + 3 design. Looking back, 
an accelerated titration design might have halved the 22-month 
accrual period in the above referent trial (1).
Women with breast or gynecological cancers are increas-
ingly self-directed and are actively searching for best radiation 
services that optimally reduce radiation-related adverse events 
better than existing therapies. For this particular type of 
consumer, quality radiation service must be a beginning step 
(8). The movement away from existing radiation technology 
to less toxic machinery like intensity-modulated radiation 
therapy (IMRT) or stereotactic ablative radiosurgery (SABR) 
has altered radiation-related adverse event rates both in and out 
of clinical trials. Consumer demand has been met, but IMRT 
and SABR technology must be integrated slowly into cancer 
research. Quality radiation service for IMRT and SABR lags 
behind quality assurance, even in clinical trials (8). Until the 
quality service-assurance gap narrows, the mixing of radiation 
platforms in early phase radiotherapy cancer trial research 
should be avoided so that vital radiation-agent interactions 
could not be masked by overrepresented or by underrepresented 
radiation technology in an early phase cancer trial. While con-
sumers have used—and will continue to utilize—radiotherapy 
proxies to demand treatment for best radiation service, it 
remains debated whether early phase radiotherapy trials should 
meet consumers where their demands are, or rather, whether 
to interrogate radiation technologies in stepwise early phase 
clinical trials.
Given this context, the articles in this Frontiers in Oncology 
Research Topic address open questions pertaining breast and 
gynecological cancer epidemiology, personalized medicine, and 
innovative therapeutic interventions.
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